Harnessing nanomedicine for therapeutic intervention in glioblastoma

References

• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109. doi:10.1007/s00401-007-0243-4.
   PubMed Web of Science ®Google Scholar
• Sanai N, Nguyen T, Ihrie RA, et al. Corridors of migrating neurons in the human brain and their decline during infancy. Nature. 2011;478:382–386. doi:10.1038/nature10487.
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507. doi:10.1056/NEJMra0708126.
   PubMed Web of Science ®Google Scholar
• Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683–2710. doi:10.1101/gad.1596707.
   PubMed Web of Science ®Google Scholar
• Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23:1985–1996. doi:10.1158/1055-9965.EPI-14-0275.
   PubMed Web of Science ®Google Scholar
• Ferguson SD. Malignant gliomas: diagnosis and treatment. Dis Mon. 2011;57:558–569. doi:10.1016/j.disamonth.2011.08.020.
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19:764–772. doi:10.1158/1078-0432.CCR-12-3002.
   PubMed Web of Science ®Google Scholar
• Brennan CW, Verhaak RGW, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–477. doi:10.1016/j.cell.2013.09.034.
   PubMed Web of Science ®Google Scholar
• Minniti G, Muni R, Lanzetta G, et al. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 2009;29:5171–5184.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Johnson JR, Pazdur R. Food and drug administration drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005;11:6767–6771. doi:10.1158/1078-0432.CCR-05-0722.
   PubMed Web of Science ®Google Scholar
• Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190–198. doi:10.3171/jns.2001.95.2.0190.
   PubMed Web of Science ®Google Scholar
• Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392–401. doi:10.1016/S1470-2045(06)70665-9.
   PubMed Web of Science ®Google Scholar
• Stummer W, Reulen H-J, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008;62: 564–576; discussion 564–576. doi:10.1227/01.neu.0000317304.31579.17
   PubMed Web of Science ®Google Scholar
• Livne O, Harel R, Hadani M, et al. Intraoperative magnetic resonance imaging for resection of intra-axial brain lesions: a decade of experience using low-field magnetic resonance imaging, Polestar N-10, 20, 30 systems. World Neurosurg. 2014;82:770–776. doi:10.1016/j.wneu.2014.02.004.
   PubMed Web of Science ®Google Scholar
• Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 2011;12:997–1003. doi:10.1016/S1470-2045(11)70196-6.
   PubMed Web of Science ®Google Scholar
• Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130:2596–2606. doi:10.1093/brain/awm204.
   PubMed Web of Science ®Google Scholar
• Scott JN, Rewcastle NB, Brasher PM, et al. Long-term glioblastoma multiforme survivors: a population-based study. Can J Neurol Sci. 1998;25:197–201.
   PubMed Web of Science ®Google Scholar
• Roy S, Lahiri D, Maji T, et al. Recurrent glioblastoma: where we stand. South Asian J Cancer. 2015;4:163–173. doi:10.4103/2278-330X.175953.
   PubMed Web of Science ®Google Scholar
• Heimer L. The human brain and spinal cord: functional neuroanatomy and dissection guide. Springer Science & Business Media. 2012 [cited 2016 Mar 5]. Available from: https://books.google.com/books?hl=en‎&id=dMvkBwAAQBAJ&pgis=1
   Google Scholar
• Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7:41–53. doi:10.1038/nrn1824.
   PubMed Web of Science ®Google Scholar
• Bernacki J, Dobrowolska A, Nierwińska K, et al. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep. 2008;60:600–622.
   PubMed Web of Science ®Google Scholar
• Keaney J, Campbell M. The dynamic blood-brain barrier. Febs J. 2015;282:4067–4079. doi:10.1111/febs.13412.
   PubMed Web of Science ®Google Scholar
• Mergenthaler P, Lindauer U, Dienel GA, et al. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci. 2013;36:587–597. doi:10.1016/j.tins.2013.07.001.
   PubMed Web of Science ®Google Scholar
• Kimelberg HK, Nedergaard M. Functions of astrocytes and their potential as therapeutic targets. Neurotherapeutics. 2010;7:338–353. doi:10.1016/j.nurt.2010.07.006.
   PubMed Web of Science ®Google Scholar
• Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19:1584–1596. doi:10.1038/nm.3407.
   PubMed Web of Science ®Google Scholar
• Ivey NS, MacLean AG, Lackner AA. Acquired immunodeficiency syndrome and the blood-brain barrier. J Neurovirol. 2009;15:111–122. doi:10.1080/13550280902769764.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev. 2012;64:640–665. doi:10.1016/j.addr.2011.11.010.
   PubMed Web of Science ®Google Scholar
• Begley DJ. Brightman MW. Structural and functional aspects of the blood-brain barrier. Prog Drug Res Fortschritte Der Arzneimittelforschung Progrès Des Rech Pharm. 2003 [cited 2016 Jan 8];61:39–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14674608
   PubMedGoogle Scholar
• Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2003;3:90–105,51. doi:10.1124/mi.3.2.90.
   PubMedGoogle Scholar
• Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci. 2000;89:1371–1388. doi:10.1002/1520-6017(200011)89:11<1371::AID-JPS1>3.0.CO;2-D.
   PubMed Web of Science ®Google Scholar
• Jiang X, Xin H, Ren Q, et al. Nanoparticles of 2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials. 2014;35:518–529. doi:10.1016/j.biomaterials.2013.09.094.
   PubMed Web of Science ®Google Scholar
• Lu W, Xiong C, Zhang R, et al. Receptor-mediated transcytosis: a mechanism for active extravascular transport of nanoparticles in solid tumors. J Control Release. 2012;161:959–966. doi:10.1016/j.jconrel.2012.05.014.
   PubMed Web of Science ®Google Scholar
• Descamps L, Dehouck MP, Torpier G, et al. Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells. Am J Physiol. 1996;270:1149–1158.
   PubMed Web of Science ®Google Scholar
• Dehouck B, Fenart L, Dehouck M-P, et al. A new function for the LDL receptor: transcytosis of LDL across the blood–brain barrier. J Cell Biol. 1997;138:877–889. doi:10.1083/jcb.138.4.877.
   PubMed Web of Science ®Google Scholar
• Stockwell J, Abdi N, Lu X, et al. Novel central nervous system drug delivery systems. Chem Biol Drug Des. 2014;83:507–520. doi:10.1111/cbdd.12268.
   PubMed Web of Science ®Google Scholar
• Lu W. Adsorptive-mediated brain delivery systems. Curr Pharm Biotechnol. [Internet]. 2012;13:2340–2348. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23016640
   PubMed Web of Science ®Google Scholar
• Hervé F, Ghinea N, Scherrmann J-M. CNS delivery via adsorptive transcytosis. Aaps J. 2008;10:455–472. doi:10.1208/s12248-008-9055-2.
   PubMed Web of Science ®Google Scholar
• De Vries HE, Kooij G, Frenkel D, et al. Inflammatory events at blood-brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical disease. Epilepsia. 2012;53(Suppl 6):45–52. doi:10.1111/j.1528-1167.2012.03702.x.
   PubMed Web of Science ®Google Scholar
• Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol. 2000;2:45–59.
   PubMed Web of Science ®Google Scholar
• Ningaraj NS, Rao M, Hashizume K, et al. Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol Exp Ther. 2002;301:838–851.
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445–1453. doi:10.2353/ajpath.2007.070011.
   PubMed Web of Science ®Google Scholar
• Dhermain FG, Hau P, Lanfermann H, et al. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9:906–920. doi:10.1016/S1474-4422(10)70181-2
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136–151. doi:10.1016/j.addr.2010.04.009.
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–284. doi:10.1016/S0168-3659(99)00248-5.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751–760. doi:10.1038/nnano.2007.387.
   PubMed Web of Science ®Google Scholar
• Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev. 2011;63:161–169. doi:10.1016/j.addr.2010.09.003.
   PubMed Web of Science ®Google Scholar
• Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2011;63:170–183. doi:10.1016/j.addr.2010.10.008.
   PubMed Web of Science ®Google Scholar
• Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm off J Arbeitsgemeinschaft FüR Pharm Verfahrenstechnik Ev. 2009;71:409–419. doi:10.1016/j.ejpb.2008.11.010.
   Web of Science ®Google Scholar
• Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63:131–135. doi:10.1016/j.addr.2010.03.011.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yan Z, Wei D, et al. Tumor-penetrating peptide functionalization enhances the anti-glioblastoma effect of doxorubicin liposomes. Nanotechnology. 2013;24:405101. doi:10.1088/0957-4484/24/40/405101.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lu W. Recent advances in brain tumor-targeted nano-drug delivery systems. Expert Opin Drug Deliv. 2012;9671–9686. doi:10.1517/17425247.2012.682726.
   Web of Science ®Google Scholar
• Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci. 1998;95:4607–4612. doi:10.1073/pnas.95.8.4607.
   PubMed Web of Science ®Google Scholar
• Claes A, Idema AJ, Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol. 2007;114:443–458. doi:10.1007/s00401-007-0293-7.
   PubMed Web of Science ®Google Scholar
• Bradley WG. Achieving gross total resection of brain tumors: intraoperative MR Imaging can make a big difference. AJNR Am J Neuroradiol. 2002 [cited 2016 Mar 6];23:48–349. Available from: http://www.ajnr.org/content/23/3/348.full
   Google Scholar
• Giese A, Bjerkvig R, Berens ME, et al. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol. 2003;21:1624–3. doi:10.1200/JCO.2003.05.063.
   PubMed Web of Science ®Google Scholar
• Thorne RG, Nicholson C. In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc Natl Acad Sci U S A. 2006;103:5567–5572. doi:10.1073/pnas.0509425103.
   PubMed Web of Science ®Google Scholar
• Nance EA, Woodworth GF, Sailor KA, et al. A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci Transl Med. 2012;4:149ra119. doi:10.1126/scitranslmed.3003594.
   PubMed Web of Science ®Google Scholar
• Mizrahy S, Goldsmith M, Leviatan-Ben-Arye S, et al. Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. Nanoscale. 2014;6:3742–3752. doi:10.1039/c3nr06102g.
   PubMed Web of Science ®Google Scholar
• Mizrahy S, Raz SR, Hasgaard M, et al. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J Control Release. 2011;156:231–238. doi:10.1016/j.jconrel.2011.06.031.
   PubMed Web of Science ®Google Scholar
• Landesman-Milo D, Goldsmith M, Leviatan Ben-Arye S, et al. Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Lett. 2013;334:221–227. doi:10.1016/j.canlet.2012.08.024.
   PubMed Web of Science ®Google Scholar
• Cohen ZR, Ramishetti S, Peshes-Yaloz N, et al. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano. 2015;9:1581–1591. doi:10.1021/nn506248s.
   PubMed Web of Science ®Google Scholar
• Menei P, Jadaud E, Faisant N, et al. Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. Cancer. 2004;100:405–410. doi:10.1002/cncr.11922.
   PubMed Web of Science ®Google Scholar
• Scott AW, Tyler BM, Masi BC, et al. Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model. Biomaterials. 2011;32:2532–2539. doi:10.1016/j.biomaterials.2010.12.020.
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine(BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79–88. doi:10.1093/neuonc/5.2.79.
   PubMed Web of Science ®Google Scholar
• Brem S, Tyler B, Li K, et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol. 2007;60:643–650.10.1007/s00280-006-0407-2.
   PubMed Web of Science ®Google Scholar
• Kim GY, Tyler BM, Tupper MM, et al. Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. J Control Release. 2007;123:172–178. doi:10.1016/j.jconrel.2007.08.003.
   PubMed Web of Science ®Google Scholar
• Tyler B, Fowers KD, Li KW, et al. A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats. J Neurosurg. 2010;113:210–217. doi:10.3171/2009.11.JNS08162.
   PubMed Web of Science ®Google Scholar
• Recinos VR, Tyler BM, Bekelis K, et al. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Neurosurgery. 2010;66: 530–537; discussion 537. doi:10.1227/01.NEU.0000365263.14725.39
   PubMed Web of Science ®Google Scholar
• Goldsmith M, Abramovitz L, Peer D. Precision nanomedicine in neurodegenerative diseases. ACS Nano. 2014;8:1958–1965. doi:10.1021/nn501292z.
   PubMed Web of Science ®Google Scholar
• Alex AT, Joseph A, Shavi G, et al. Development and evaluation of carboplatin-loaded PCL nanoparticles for intranasal delivery. Drug Deliv. 2015;1–10. doi:10.3109/10717544.2014.948643.
   PubMedGoogle Scholar
• Kanazawa T, Morisaki K, Suzuki S, et al. Prolongation of life in rats with malignant glioma by intranasal siRNA/drug codelivery to the brain with cell-penetrating peptide-modified micelles. Mol Pharm. 2014;11:1471–1478. doi:10.1021/mp400644e.
   PubMed Web of Science ®Google Scholar
• Geldenhuys W, Mbimba T, Bui T, et al. Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers. J Drug Target. 2011;19:837–845. doi:10.3109/1061186X.2011.589435.
   PubMed Web of Science ®Google Scholar
• Ying X, Wen H, Lu W-L, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release. 2010;141:183–192. doi:10.1016/j.jconrel.2009.09.020.
   PubMed Web of Science ®Google Scholar
• Zhang B, Sun X, Mei H, et al. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. Biomaterials. 2013;34:9171–9182. doi:10.1016/j.biomaterials.2013.08.039.
   PubMed Web of Science ®Google Scholar
• Beier CP, Schmid C, Gorlia T, et al. RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma–a phase II study. BMC Cancer. 2009;9:308. doi:10.1186/1471-2407-9-308.
   PubMed Web of Science ®Google Scholar
• Ananda S, Nowak AK, Cher L, et al. Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. J Clin Neurosci. 2011;18:1444–1448. doi:10.1016/j.jocn.2011.02.026.
   PubMed Web of Science ®Google Scholar
• Chua SL, Rosenthal MA, Wong SS, et al. Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro Oncol. 2004;6:38–43. doi:10.1215/S1152851703000188.
   PubMed Web of Science ®Google Scholar
• Hau P, Fabel K, Baumgart U, et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer. 2004;100:1199–1207. doi:10.1002/cncr.20073.
   PubMed Web of Science ®Google Scholar
• Fabel K, Dietrich J, Hau P, et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer. 2001;92:1936–1942.
   PubMed Web of Science ®Google Scholar
• Henkin RI. Intranasal delivery to the brain. Nat Biotechnol. 2011;29:480. doi:10.1038/nbt.1866.
   PubMed Web of Science ®Google Scholar
• Hanson LR, Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9 Suppl 3:S5. doi:10.1186/1471-2202-9-S3-S5.
   PubMed Web of Science ®Google Scholar
• Vaka SRK, Sammeta SM, Day LB, et al. Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. J Pharm Sci. 2009;98:3640–3646. doi:10.1002/jps.21674
   PubMed Web of Science ®Google Scholar
• Frey WH, Liu J, Chen X, et al. Delivery of 125 I-NGF to the brain via the olfactory route. Drug Deliv. 2008;4:87–92. doi:10.3109/10717549709051878.
   Web of Science ®Google Scholar
• Thorne RG, Pronk GJ, Padmanabhan V, et al. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127:481–496. doi:10.1016/j.neuroscience.2004.05.029.
   PubMed Web of Science ®Google Scholar
• Ross TM, Martinez PM, Renner JC, et al. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol. 2004;151:66–77. doi:10.1016/j.jneuroim.2004.02.011.
   PubMed Web of Science ®Google Scholar
• Van Woensel M, Wauthoz N, Rosière R, et al. Formulations for intranasal delivery of pharmacological agents to combat brain disease: a new opportunity to tackle GBM? Cancers (Basel). 2013;5:1020–1048. doi:10.3390/cancers5031020.
   PubMedGoogle Scholar
• Karim R, Palazzo C, Evrard B, et al. Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art. J Control Release. 2016;227:23–37. doi:10.1016/j.jconrel.2016.02.026.
   PubMed Web of Science ®Google Scholar
• McDannold N, Arvanitis CD, Vykhodtseva N, et al. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res. 2012;72:3652–3663. doi:10.1158/0008-5472.CAN-12-0128.
   PubMed Web of Science ®Google Scholar
• Aryal M, Vykhodtseva N, Zhang Y-Z, et al. Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood-tumor and blood-brain barriers improve outcomes in a rat glioma model. J Control Release. 2013;169:103–111. doi:10.1016/j.jconrel.2013.04.007.
   PubMed Web of Science ®Google Scholar
• Weinstein S, Toker IA, Emmanuel R, et al. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc Natl Acad Sci U S A. 2015. doi:10.1073/pnas.1519273113
   Web of Science ®Google Scholar
• Ramishetti S, Kedmi R, Goldsmith M, et al. Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles. ACS Nano. 2015;9:6706–6716. doi:10.1021/acsnano.5b02796.
   PubMed Web of Science ®Google Scholar
• Wittrup KD, Thurber GM, Schmidt MM, et al. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol. 2012;503:255–268. doi:10.1016/B978-0-12-396962-0.00010-0.
   PubMed Web of Science ®Google Scholar
• Monteiro N, Martins A, Reis RL, et al. Liposomes in tissue engineering and regenerative medicine. J R Soc Interface. 2014;11:20140459.
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:102. doi:10.1186/1556-276X-8-102
   PubMed Web of Science ®Google Scholar
• Patel T, Zhou J, Piepmeier JM, et al. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev. 2012;64:701–705. doi:10.1016/j.addr.2011.12.006.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24:1–16. doi:10.1007/s11095-006-9132-0.
   PubMed Web of Science ®Google Scholar
• Tyrrell ZL, Shen Y, Radosz M. Fabrication of micellar nanoparticles for drug delivery through the self-assembly of block copolymers. Prog Polym Sci. 2010;35:1128–1143. doi:10.1016/j.progpolymsci.2010.06.003.
   Web of Science ®Google Scholar
• Hainfeld JF, Smilowitz HM, O’Connor MJ, et al. Gold nanoparticle imaging and radiotherapy of brain tumors in mice. Nanomed (Lond). 2013;8:1601–1609. doi:10.2217/nnm.12.165.
   PubMed Web of Science ®Google Scholar
• Weinstein JS, Varallyay CG, Dosa E, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab. 2010;30:15–35. doi:10.1038/jcbfm.2009.192.
   PubMed Web of Science ®Google Scholar
• Kaluzova M, Bouras A, Machaidze R, et al. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles. Oncotarget. 2015;6:8788–8806. doi:10.18632/oncotarget.3554.
   PubMed Web of Science ®Google Scholar
• Juzenas P, Chen W, Sun Y-P, et al. Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. Adv Drug Deliv Rev. 2008;60:1600–1614. doi:10.1016/j.addr.2008.08.004.
   PubMed Web of Science ®Google Scholar
• Cai W, Shin D-W, Chen K, et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 2006;6:669–676. doi:10.1021/nl052405t.
   PubMed Web of Science ®Google Scholar
• Fung LK, Saltzman WM. Polymeric implants for cancer chemotherapy. Adv Drug Deliv Rev. 1997;26:209–230. doi:10.1016/S0169-409X(97)00036-7.
   PubMed Web of Science ®Google Scholar
• Fung LK, Shin M, Tyler B, et al. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-l-nitrosourea in the rat brain. Pharm Res. 1996;13:671–682.10.1023/A:1016083113123.
   PubMed Web of Science ®Google Scholar
• Mamot C, Nguyen JB, Pourdehnad M, et al. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol. 2004;68:1–9. doi:10.1023/B:NEON.0000024743.56415.4b.
   PubMed Web of Science ®Google Scholar
• Sawyer AJ, Saucier-Sawyer JK, Booth CJ, et al. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Deliv Transl Res. 2011;1:34–42. doi:10.1007/s13346-010-0001-3.
   PubMed Web of Science ®Google Scholar
• Qin Y, Fan W, Chen H, et al. In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J Drug Target. 2010;18:536–549. doi:10.3109/10611861003587235.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2:3–14. doi:10.1602/neurorx.2.1.3.
   PubMedGoogle Scholar
• Ulbrich K, Hekmatara T, Herbert E, et al. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm. 2009;71:251–256. doi:10.1016/j.ejpb.2008.08.021.
   PubMed Web of Science ®Google Scholar
• Porru M, Zappavigna S, Salzano G, et al. Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. Oncotarget. 2014;5:10446–10459. doi:10.18632/oncotarget.2182.
   PubMed Web of Science ®Google Scholar
• Cui Y, Xu Q, Chow PK-H, et al. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials. 2013;34:8511–8520. doi:10.1016/j.biomaterials.2013.07.075.
   PubMed Web of Science ®Google Scholar
• Bertrand Y, Currie J-C, Poirier J, et al. Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1. Br J Cancer. 2011;105:1697–07. doi:10.1038/bjc.2011.427.
   PubMed Web of Science ®Google Scholar
• Geldenhuys W, Wehrung D, Groshev A, et al. Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers. Pharm Dev Technol. 2015;20:497–506. doi:10.3109/10837450.2014.892130.
   PubMed Web of Science ®Google Scholar
• Grover A, Hirani A, Pathak Y, et al. Brain-targeted delivery of docetaxel by glutathione-coated nanoparticles for brain cancer. AAPS PharmSciTech. 2014;15:1562–1568. doi:10.1208/s12249-014-0165-0.
   PubMed Web of Science ®Google Scholar
• Thiyagarajan V, Lin S-X, Lee C-H, et al. A focal adhesion kinase inhibitor 16-hydroxy-cleroda-3,13-dien-16,15-olide incorporated into enteric-coated nanoparticles for controlled anti-glioma drug delivery. Colloids Surf B Biointerfaces. 2016;141:120–131. doi:10.1016/j.colsurfb.2016.01.038.
   PubMed Web of Science ®Google Scholar
• Rosenblum D, Peer D. Omics-based nanomedicine: the future of personalized oncology. Cancer Lett. 2014;352:126–136. doi:10.1016/j.canlet.2013.07.029.
   PubMed Web of Science ®Google Scholar
• Peer D. Precision medicine–delivering the goods? Cancer Lett. 2014;352:2–3. doi:10.1016/j.canlet.2014.04.011.
   PubMed Web of Science ®Google Scholar